Supplemental Material

Temporal trajectory of systolic blood pressure and outcomes in acute intracerebral hemorrhage: ATACH-2 trial cohort

Kanta Tanaka, MD, PhD 1; Masatoshi Koga, MD, PhD 1; Mayumi Fukuda-Doi, MD, PhD 1,2; Adnan I. Qureshi, MD, PhD 3; Haruko Yamamoto, MD, PhD 2; Kaori Miwa, MD, PhD 1; Masafumi Ihara, MD, PhD 5; Kazunori Toyoda, MD, PhD 1 for the ATACH-2 Trial Investigators

1 Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan
2 Department of Data Science, National Cerebral and Cardiovascular Center, Suita, Japan
3 Zeenat Qureshi Stroke Research Center, University of Minnesota, Minneapolis, MN, USA
4 Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan
Supplemental Methods

Blood pressure was monitored regularly with an automated blood pressure monitor. Blood pressure was measured with subjects in a recumbent position and with elevation of the head of the bed not exceeding 15°. Intra-arterial blood pressure recording was not mandated but could have been used by the treating physician based on medical indications. Blood pressure measurements were to be taken on the following schedule:

- During the first hour after nicardipine started:
  a) Every 5 minutes for the first 15 minutes after nicardipine was started
  b) Every 15 minutes for the remainder of the first hour, unless nicardipine dose was being adjusted

- Every 5 minutes (recommended) to 15 minutes (mandatory) during nicardipine dose adjustment

- At least every 30 minutes while receiving nicardipine

- After the 24-hour study drug maintenance infusion period had ended, every 30 minutes until systolic blood pressure was increased by 10 mmHg over the blood pressure measurement taken at the end of infusion, alternate antihypertensive therapy was initiated, or a maximum of 24 hours had elapsed.
Table S1. Differences between the actual timing of blood pressure measurement and the forcefully set time points

| Time point # | Forcefully set time point (min) | Actual timing from randomization (min) | Number of missing values in hourly maximum SBP |
|--------------|---------------------------------|----------------------------------------|-----------------------------------------------|
| 0            | -90 (at hospital arrival)       | Median -89 (IQR, -127, -61)           | 1                                             |
| 1            | 0 (at randomization)            | At randomization                       | 0                                             |
| 2            | 15                              | 0–15                                   | 78                                            |
| 3            | 30                              | 16–30                                  | 95                                            |
| 4            | 45                              | 31–45                                  | 69                                            |
| 5            | 60                              | 46–60                                  | 66                                            |
| 6            | 120                             | 61–120                                 | 16                                            |
| 7            | 180                             | 121–180                                | 8                                             |
| 8            | 240                             | 181–240                                | 13                                            |
| 9            | 300                             | 241–300                                | 16                                            |
| 10           | 360                             | 301–360                                | 23                                            |
| 11           | 420                             | 361–420                                | 19                                            |
| 12           | 480                             | 421–480                                | 15                                            |
| 13           | 540                             | 481–540                                | 17                                            |
| 14           | 600                             | 541–600                                | 15                                            |
| 15           | 660                             | 601–660                                | 17                                            |
| 16           | 720                             | 661–720                                | 8                                             |
| 17           | 780                             | 721–780                                | 12                                            |
| 18           | 840                             | 781–840                                | 11                                            |
| 19           | 900                             | 841–900                                | 13                                            |
| 20           | 960                             | 901–960                                | 16                                            |
| 21           | 1020                            | 961–1020                               | 13                                            |
| 22           | 1080                            | 1021–1080                              | 18                                            |
| 23           | 1140                            | 1081–1140                              | 18                                            |
| 24           | 1200                            | 1141–1200                              | 17                                            |
| 25           | 1260                            | 1201–1260                              | 16                                            |
| 26           | 1320                            | 1261–1320                              | 21                                            |
| 27           | 1380                            | 1321–1380                              | 30                                            |
| 28           | 1440                            | 1381–1440                              | 25                                            |

Abbreviations: IQR, interquartile range; SBP, systolic blood pressure.
| Model # | Groups | Polynomials | BIC   | $2 \times \Delta$BIC | Group 1 (n) | Group 2 (n) | Group 3 (n) | Group 4 (n) | Group 5 (n) | Remarks                                      |
|---------|--------|-------------|-------|------------------------|-------------|-------------|-------------|-------------|-------------|-----------------------------------------------|
| 1       | 1      | 3           | -126582.4 | 1000                   | --          | --          | --          | --          | --          | BIC<sub>max</sub> in 1-group models           |
| 2       | 2      | 2 3         | -122995.9 | 7173                   | 512         | 488         | --          | --          | --          | BIC<sub>max</sub> in 2-group models           |
| 3       | 3      | 3 3 1       | -121852.9 | 2286                   | 485         | 381         | 134         | --          | --          | BIC<sub>max</sub> in 3-group models           |
| 4       | 4      | 3 1 1 3     | -121623.2 | 459.4                  | 476         | 127         | 153         | 244         | --          |                                               |
| 5       | 4      | 3 2 3 3     | -121472.5 | 301.4                  | 265         | 100         | 368         | 267         | --          |                                               |
| 6       | 4      | 2 3 3 2     | -121469.1 | 6.8                    | 299         | 411         | 157         | 133         | --          |                                               |
| 7       | 5      | 2 1 1 3 3   | -121414.4 | 109.4                  | 110         | 131         | 139         | 380         | 240         |                                               |
| 8       | 5      | 1 2 1 3 3   | -121414.4 | 0                      | 139         | 110         | 131         | 240         | 380         |                                               |
| 9       | 5      | 1 1 3 2 3   | -121405.7 | 17.4                   | 143         | 32          | 422         | 91          | 312         |                                               |
| 10      | 5      | 2 1 3 2 3   | -121400.5 | 10.4                   | 91          | 161         | 407         | 90          | 251         |                                               |
| 11      | 5      | 3 2 3 1 2   | -121400.5 | 0                      | 250         | 91          | 407         | 161         | 91          |                                               |
| 12      | 5      | 3 1 1 3 2   | -121397   | 7                      | 416         | 97          | 199         | 207         | 81          |                                               |
| 13      | 5      | 2 3 3 2 1   | -121363.5 | 67                     | 146         | 383         | 145         | 289         | 37          |                                               |
| 14      | 5      | 3 3 1 3 3   | -121286.9 | 153.2                  | 0           | 390         | 148         | 157         | 305         |                                               |
| 15      | 5      | 3 2 2 3 2   | -121259.1 | 55.6                   | 350         | 59          | 76          | 400         | 115         |                                               |
| 16      | 5      | 3 3 3 3 2   | -121229.3 | 59.6                   | 0           | 347         | 399         | 141         | 113         |                                               |
| 17      | 5      | 3 2 3 3 3   | -121223.8 | 11                     | 0           | 168         | 382         | 142         | 308         |                                               |
| 18      | 5      | 3 3 2 1 3   | -121177.4 | 92.8                   | 198         | 356         | 41          | 103         | 302         |                                               |
| 19      | 5      | 3 1 1 3 3   | -121090.7 | 173.4                  | 378         | 126         | 99          | 139         | 258         | BIC<sub>max</sub> in 5-group models; used for sensitivity analyses |
| 20      | 4      | 3 3 3 3     | -121087.9 | 5.6                    | 298         | 395         | 134         | 173         | --          | BIC<sub>max</sub> in 4-group models; used for main analyses |

Abbreviations: BIC, Bayesian Information Criteria.
| Use of secondary antihypertensive agents (number) | Group 1: Moderate SBP (n=298) | Group 2: Moderate-to-low SBP (n=395) | Group 3: High-to-low SBP (n=134) | Group 4: High SBP (n=173) |
|-----------------------------------------------|-------------------------------|-------------------------------------|---------------------------------|--------------------------|
| Use of secondary antihypertensive agents      | 38                            | 82                                  | 66                              | 31                       |
| Secondary antihypertensive agents             |                               |                                     |                                 |                          |
| Labetalol                                     | 23 (60.5%)                    | 46 (56.1%)                          | 34 (51.5%)                      | 18 (58.1%)               |
| Diltiazem                                     | 1 (2.6%)                      | 15 (18.3%)                          | 16 (24.2%)                      | 1 (3.2%)                 |
| Urapidil                                      | 2 (5.3%)                      | 5 (6.1%)                            | 7 (10.6%)                       | 2 (6.5%)                 |
| Others                                        | 12 (31.6%)                    | 16 (19.5%)                          | 9 (13.6%)                       | 10 (32.3%)               |

Abbreviations: SBP, systolic blood pressure.
Table S4. Severity of acute kidney injury within 7 days

| Acute kidney injury within 7 days (number) | All (n=1000) | Group 1: Moderate SBP (n=298) | Group 2: Moderate-to-low SBP (n=395) | Group 3: High-to-low SBP (n=134) | Group 4: High SBP (n=173) |
|------------------------------------------|--------------|-------------------------------|-------------------------------------|---------------------------------|--------------------------|
| Stages                                   |              |                               |                                     |                                 |                          |
| 1                                        | 104 (82.5%)  | 28 (82.4%)                    | 24 (77.4%)                          | 31 (83.8%)                      | 21 (87.5%)               |
| 2                                        | 15 (11.9%)   | 3 (8.8%)                      | 5 (16.1%)                           | 5 (13.5%)                       | 2 (8.3%)                 |
| 3                                        | 7 (5.6%)     | 3 (8.8%)                      | 2 (6.5%)                            | 1 (2.7%)                        | 1 (4.2%)                 |

Abbreviations: SBP, systolic blood pressure.
## Table S5. Details of renal adverse events within 7 days

| Renal adverse events within 7 days (number) | All (n=1000) | Group 1: Moderate SBP (n=298) | Group 2: Moderate-to-low SBP (n=395) | Group 3: High-to-low SBP (n=134) | Group 4: High SBP (n=173) |
|-------------------------------------------|--------------|-------------------------------|-------------------------------------|--------------------------------|--------------------------|
| **MedDRA Preferred Terms**                |              |                               |                                     |                                |                          |
| Blood creatinine increased                | 7 (12.7%)    | 2 (20.0%)                     | 2 (11.8%)                           | 2 (10.0%)                      | 1 (12.5%)                |
| Blood urea increased                      | 5 (9.1%)     | 3 (30.0%)                     | 1 (5.9%)                            | 1 (5.0%)                       | 0 (0.0%)                |
| OTHER Investigations                      | 4 (7.3%)     | 2 (20.0%)                     | 1 (5.9%)                            | 0 (0.0%)                       | 1 (12.5%)                |
| OTHER Renal and urinary disorders         | 2 (3.6%)     | 0 (0.0%)                      | 1 (5.9%)                            | 0 (0.0%)                       | 1 (12.5%)                |
| Renal failure                             | 4 (7.3%)     | 0 (0.0%)                      | 1 (5.9%)                            | 2 (10.0%)                      | 1 (12.5%)                |
| Renal failure acute                       | 18 (32.7%)   | 2 (20.0%)                     | 4 (23.5%)                           | 9 (45.0%)                      | 3 (37.5%)                |
| Renal impairment                          | 9 (16.4%)    | 1 (10.0%)                     | 3 (17.6%)                           | 4 (20.0%)                      | 1 (12.5%)                |
| Urine output decreased                    | 6 (10.9%)    | 0 (0.0%)                      | 4 (23.5%)                           | 2 (10.0%)                      | 0 (0.0%)                |

Abbreviations: MedDRA, Medical Dictionary for Regulatory Activities; SBP, systolic blood pressure.
| Cardiac adverse events within 7 days (number) | All (n=1000) | Group 1: Moderate SBP (n=298) | Group 2: Moderate-to-low SBP (n=395) | Group 3: High-to-low SBP (n=134) | Group 4: High SBP (n=173) |
|---------------------------------------------|--------------|-------------------------------|-------------------------------------|---------------------------------|--------------------------|
| MedDRA Preferred Terms                      |--------------|-------------------------------|-------------------------------------|---------------------------------|--------------------------|
| Acute myocardial infarction                 | 1 (1.0%)     | 0 (0.0%)                      | 0 (0.0%)                            | 0 (0.0%)                        | 1 (5.6%)                 |
| Atrial fibrillation                         | 7 (7.1%)     | 3 (13.6%)                     | 3 (8.3%)                            | 0 (0.0%)                        | 1 (5.6%)                 |
| Bradycardia                                 | 5 (5.1%)     | 2 (9.1%)                      | 1 (2.8%)                            | 0 (0.0%)                        | 1 (5.6%)                 |
| Cardiac arrest                              | 1 (1.0%)     | 0 (0.0%)                      | 1 (2.8%)                            | 0 (0.0%)                        | 0 (0.0%)                 |
| Cardiac failure                             | 2 (2.0%)     | 0 (0.0%)                      | 0 (0.0%)                            | 2 (8.7%)                        | 0 (0.0%)                 |
| Cardiac failure congestive                  | 2 (2.0%)     | 0 (0.0%)                      | 0 (0.0%)                            | 1 (4.3%)                        | 1 (5.6%)                 |
| Cardiorespiratory arrest                    | 3 (3.0%)     | 0 (0.0%)                      | 2 (5.6%)                            | 1 (4.3%)                        | 0 (0.0%)                 |
| Chest discomfort                            | 1 (1.0%)     | 0 (0.0%)                      | 1 (2.8%)                            | 0 (0.0%)                        | 0 (0.0%)                 |
| Chest pain                                  | 4 (4.0%)     | 1 (4.5%)                      | 2 (5.6%)                            | 0 (0.0%)                        | 1 (5.6%)                 |
| Circulatory collapse                        | 2 (2.0%)     | 0 (0.0%)                      | 2 (5.6%)                            | 0 (0.0%)                        | 0 (0.0%)                 |
| Hypertension                                | 7 (7.1%)     | 3 (13.6%)                     | 3 (8.3%)                            | 0 (0.0%)                        | 1 (5.6%)                 |
| Hypotension                                 | 8 (8.1%)     | 1 (4.5%)                      | 1 (2.8%)                            | 4 (17.4%)                       | 2 (11.1%)                |
| Myocardial infarction                       | 2 (2.0%)     | 0 (0.0%)                      | 1 (2.8%)                            | 0 (0.0%)                        | 1 (5.6%)                 |
| OTHER Cardiac disorders                     | 12 (12.1%)   | 2 (9.1%)                      | 7 (19.4%)                           | 3 (13.0%)                       | 0 (0.0%)                 |
| OTHER Investigations                        | 5 (5.1%)     | 2 (9.1%)                      | 0 (0.0%)                            | 1 (4.3%)                        | 2 (11.1%)                |
| OTHER Vascular disorders                    | 3 (3.0%)     | 0 (0.0%)                      | 2 (5.6%)                            | 1 (4.3%)                        | 0 (0.0%)                 |
| Sinus tachycardia                           | 2 (2.0%)     | 2 (9.1%)                      | 0 (0.0%)                            | 0 (0.0%)                        | 0 (0.0%)                 |
| Supraventricular tachycardia                | 2 (2.0%)     | 0 (0.0%)                      | 2 (5.6%)                            | 0 (0.0%)                        | 0 (0.0%)                 |
| Tachycardia                                 | 15 (15.2%)   | 4 (18.2%)                     | 2 (5.6%)                            | 5 (21.7%)                       | 4 (22.2%)                |
| Troponin I increased                        | 1 (1.0%)     | 0 (0.0%)                      | 0 (0.0%)                            | 0 (0.0%)                        | 1 (5.6%)                 |
| Troponin increased                          | 9 (9.1%)     | 1 (4.5%)                      | 4 (11.1%)                           | 2 (8.7%)                        | 2 (11.1%)                |
| Ventricular extrasystoles                   | 3 (3.0%)     | 1 (4.5%)                      | 2 (5.6%)                            | 0 (0.0%)                        | 0 (0.0%)                 |
| Condition          | Value 1 | Value 2 | Value 3 | Value 4 | Value 5 |
|-------------------|---------|---------|---------|---------|---------|
| Ventricular tachycardia | 2 (2.0%) | 0 (0.0%) | 0 (0.0%) | 2 (8.7%) | 0 (0.0%) |

Abbreviations: MedDRA, Medical Dictionary for Regulatory Activities; SBP, systolic blood pressure.
| Causes of death          | All (n=1000) | Group 1: Moderate SBP (n=298) | Group 2: Moderate-to-low SBP (n=395) | Group 3: High-to-low SBP (n=134) | Group 4: High SBP (n=173) |
|-------------------------|--------------|-------------------------------|-------------------------------------|---------------------------------|--------------------------|
| Deaths within 3 months (number) | 67           | 17                            | 24                                  | 12                              | 14                       |
| Brain herniation        | 10 (14.9%)   | 3 (17.6%)                     | 1 (4.2%)                            | 3 (25.0%)                       | 3 (21.4%)                |
| Infection               | 5 (7.5%)     | 1 (5.9%)                      | 2 (8.3%)                            | 1 (8.3%)                        | 1 (7.1%)                 |
| Cardiovascular event    | 13 (19.4%)   | 4 (23.5%)                     | 4 (16.7%)                           | 4 (33.3%)                       | 1 (7.1%)                 |
| Respiratory arrest      | 18 (26.9%)   | 3 (17.6%)                     | 7 (29.2%)                           | 2 (16.7%)                       | 6 (42.9%)                |
| Others                  | 21 (31.3%)   | 6 (35.3%)                     | 10 (41.7%)                          | 2 (16.7%)                       | 3 (21.4%)                |

Abbreviations: SBP, systolic blood pressure.
### Table S8. Sensitivity analysis outcomes

|                        | Moderate-to-low SBP (n=378) | Moderate SBP (n=126) | High SBP (n=99) | High-to-low SBP (n=139) | High-to-moderate SBP (n=258) | P value * |
|------------------------|-----------------------------|----------------------|-----------------|-------------------------|-----------------------------|-----------|
| **Death or disability at 3 months** | 123 (33.9%, n=363) | 44 (36.4%, n=121) | 48 (50.5%, n=95) | 64 (48.1%, n=133) | 88 (35.3%, n=249) | <0.01 |
| Crude OR (95% CI)       | 1.11 (0.73–1.71); P=0.61 | 1.99 (1.26–3.15); P<0.01 | 1.81 (1.21–2.71); P<0.01 | 1.07 (0.76–1.49); P=0.70 |
| Adjusted OR (95% CI) †  | 1.82 (0.66–3.84); P=0.11 (n=108) | 2.43 (1.01–5.86); P=0.04 (n=80) | 2.60 (1.41–4.81); P=0.01 (n=125) | 1.55 (0.72–3.35); P=0.26 (n=231) |
| **Death within 3 months** | 22 (5.8%, n=378) | 9 (7.1%, n=126) | 10 (10.1%, n=99) | 12 (8.6%, n=139) | 14 (5.4%, n=258) | 0.43 |
| Crude OR (95% CI)       | 1.24 (0.56–2.78); P=0.59 | 1.82 (0.83–3.98); P=0.13 | 1.53 (0.74–3.18); P=0.25 | 0.93 (0.47–1.85); P=0.83 |
| Adjusted OR (95% CI) †  | 0.63 (0.16–2.39); P=0.49 (n=112) | 1.06 (0.24–4.59); P=0.93 (n=83) | 0.82 (0.25–2.74); P=0.74 (n=129) | 1.06 (0.28–4.04); P=0.93 (n=239) |
| **Hematoma expansion within 24 hours** | 70 (18.5%, n=378) | 28 (22.2%, n=126) | 22 (22.2%, n=99) | 18 (12.9%, n=139) | 51 (19.8%, n=258) | 0.29 |
| Crude OR (95% CI)       | 1.26 (0.77–2.06); P=0.36 | 1.26 (0.73–2.16); P=0.40 | 0.65 (0.37–1.14); P=0.13 | 1.08 (0.73–1.62); P=0.69 |
| Adjusted OR (95% CI) †  | 1.24 (0.63–2.46); P=0.53 (n=112) | 1.17 (0.52–2.65); P=0.70 (n=83) | 0.66 (0.33–1.30); P=0.23 (n=129) | 1.14 (0.56–2.28); P=0.72 (n=239) |
| **Neurological deterioration within 24 hours** | 37 (9.8%, n=378) | 15 (11.9%, n=126) | 8 (8.1%, n=99) | 18 (12.9%, n=139) | 15 (5.8%, n=258) | 0.13 |
| Crude OR (95% CI)       | 1.25 (0.66–2.35); P=0.49 | 0.81 (0.36–1.80); P=0.60 | 1.37 (0.75–2.49); P=0.30 | 0.57 (0.31–1.06); P=0.07 |
| Adjusted OR (95% CI) †  | 1.07 (0.42–2.72); P=0.88 (n=112) | 0.40 (0.11–1.43); P=0.16 (n=83) | 0.45 (0.19–1.07); P=0.07 (n=129) | 0.31 (0.11–0.88); P=0.02 (n=239) |
| **Acute kidney injury within 7 days** | 26 (6.9%, n=378) | 15 (11.9%, n=126) | 14 (14.1%, n=99) | 38 (27.3%, n=139) | 33 (12.8%, n=258) | <0.01 |
| Crude OR (95% CI)       | 1.83 (0.94–3.58); P=0.07 | 2.23 (1.12–4.45); P=0.02 | 5.09 (2.95–8.79); P<0.01 | 1.99 (1.16–3.41); P=0.01 |
| Adjusted OR (95% CI) †  | 1.50 (0.59–3.78); P=0.38 (n=112) | 1.89 (0.63–5.65); P=0.25 (n=83) | 4.31 (2.22–8.36); P<0.01 (n=129) | 2.12 (0.84–5.37); P=0.11 (n=239) |
| **Renal adverse events within 7 days** | 16 (4.2%, n=378) | 6 (4.8%, n=126) | 3 (3.0%, n=99) | 21 (15.1%, n=139) | 9 (3.5%, n=258) | <0.01 |
| Crude OR (95% CI)       | 1.13 (0.43–2.96); P=0.80 | 0.71 (0.20–2.48); P=0.58 | 4.03 (2.03–7.97); P<0.01 | 0.82 (0.36–1.88); P=0.63 |
| Adjusted OR (95% CI) †  | 1.89 (0.58–6.12); P=0.29 (n=112) | 0.48 (0.05–4.83); P=0.53 (n=83) | 2.94 (1.25–6.88); P=0.01 (n=129) | 1.31 (0.33–5.10); P=0.70 (n=239) |
| Serious renal adverse events within 7 days | 1 (0.3%, n=378) | 0 (0.0%, n=126) | 1 (1.0%, n=99) | 3 (2.2%, n=139) | 1 (0.4%, n=258) | 0.11 |
| Cardiac adverse events within 7 days | 34 (9.0%, n=378) | 11 (8.7%, n=126) | 16 (16.2%, n=99) | 23 (16.5%, n=139) | 15 (5.8%, n=258) | <0.01 |
| Crude OR (95% CI) | 1 [Reference] | 0.97 (0.47–1.97); P=0.92 | 1.95 (1.03–3.70); P=0.04 | 2.01 (1.14–3.55); P=0.01 | 0.62 (0.33–1.17); P=0.14 |
| Adjusted OR (95% CI) † | 1 [Reference] | 0.80 (0.32–2.04); P=0.64 (n=112) | 1.77 (0.64–4.88); P=0.26 (n=83) | 2.21 (1.08–4.52); P=0.03 (n=129) | 0.71 (0.26–1.93); P=0.50 (n=239) |
| Serious cardiac adverse events within 7 days | 13 (3.4%, n=378) | 0 (0.0%, n=126) | 1 (1.0%, n=99) | 5 (3.6%, n=139) | 3 (1.2%, n=258) | 0.07 |
| Brain infarction adverse events within 7 days | 2 (0.5%, n=378) | 3 (2.4%, n=126) | 0 (0.0%, n=99) | 1 (0.7%, n=139) | 0 (0.0%, n=258) | 0.06 |

* Pearson χ² test.
† Adjusting covariates are sex, age, recruited sites (Asia or non-Asia), prescribed antihypertensive medication, baseline NIH Stroke Scale score, white blood cell count, serum creatinine, baseline hematoma volume, time from onset to randomization, treatment assignment (intensive or standard SBP lowering), SBP at randomization, maximum dosage of nicardipine, use of secondary antihypertensive agents, and mechanical ventilation.

Abbreviations: CI, confidence interval; OR, odds ratio; SBP, systolic blood pressure.
Abbreviations: SBP, systolic blood pressure.

Figure S1. Study flow chart

Patients with intraparenchymal hematoma showing a volume <60 mL, Glasgow Coma Scale score ≥5, and SBP ≥180 mmHg on hospital arrival, N=1000

Randomization

Intensive SBP lowering (SBP target of 110 to 139 mmHg), n=500

Standard SBP lowering (SBP target of 140 to 179 mmHg), n=500

Group-based trajectory modeling

n=33  n=265  n=114  n=20  n=3  n=170

Group 1
Moderate SBP
n=298

Group 2
Moderate-to-low SBP
n=395

Group 3
High-to-low SBP
n=134

Group 4
High SBP
n=173
Figure S2. Modified Rankin Scale and acute kidney injury and renal and cardiac adverse events

Abbreviations: AE, adverse event; AKI, acute kidney injury.
Figure S3. Trajectory groups for sensitivity analysis

Abbreviations: CI, confidence interval; SBP, systolic blood pressure.

| Group | n (%)     | Average posterior probability | Odds of correct classification | Estimated proportion for each group |
|-------|-----------|-------------------------------|-------------------------------|-------------------------------------|
| 1     | 378 (37.8%) | 0.97                          | 55.91                         | 37.6%                               |
| 2     | 126 (12.6%) | 0.87                          | 47.18                         | 12.2%                               |
| 3     | 99 (9.9%)   | 0.88                          | 69.58                         | 9.9%                                |
| 4     | 139 (13.9%) | 0.94                          | 95.71                         | 14.4%                               |
| 5     | 258 (25.8%) | 0.92                          | 33.79                         | 25.9%                               |